Cargando…

Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis

We assessed whether comparative efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) plus metformin versus BIAsp 30 monotherapy differed for patients with type 2 diabetes mellitus (T2DM) inadequately controlled with oral antidiabetic drugs with different cardiovascular risk scores and differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Lixin, Chang, Baocheng, Chen, Li, Yang, Liyong, Liu, Yu, Feng, Bo, He, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893025/ https://www.ncbi.nlm.nih.gov/pubmed/33602996 http://dx.doi.org/10.1038/s41598-021-83410-x

Ejemplares similares

Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: A consensus statement
por: Brito, Miguel, et al.
Publicado: (2011)

A commentary on the “consensus statement” regarding the use of BIAsp30
por: Kawamori, Ryuzo
Publicado: (2010)

Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement
por: Unnikrishnan, A G, et al.
Publicado: (2009)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
por: Valensi, Paul
Publicado: (2009)

Patient treatment satisfaction after switching to NovoMix(®) 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
por: Brod, Meryl, et al.
Publicado: (2010)

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
por: Home, Philip D., et al.
Publicado: (2022)

An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin
por: Chraibi, Abdelmjid, et al.
Publicado: (2017)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
por: Shao, Hui, et al.
Publicado: (2022)

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
por: McCrimmon, Rory J., et al.
Publicado: (2022)

Improved patient‐reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
por: Polonsky, William H., et al.
Publicado: (2022)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

Erratum to: An RCT Investigating Patient-Driven Versus Physician-Driven Titration of BIAsp 30 in Patients with Type 2 Diabetes Uncontrolled Using NPH Insulin
por: Chraibi, Abdelmjid, et al.
Publicado: (2017)

Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials
por: Fulcher, Greg, et al.
Publicado: (2018)

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
por: McCrimmon, Rory J., et al.
Publicado: (2022)

A 32-Week Randomized Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp 30) Versus Basal–Bolus Therapy in Insulin-Naïve Patients with Type 2 Diabetes
por: Linjawi, Sultan, et al.
Publicado: (2017)

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
por: Rosenstock, Julio, et al.
Publicado: (2021)

Comparison of Sleeve Gastrectomy vs Intensive Lifestyle Modification in Patients With a BMI of 30 to Less Than 35
por: Stenberg, Erik, et al.
Publicado: (2022)

Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator
por: Chen, Yu-Ching, et al.
Publicado: (2015)

Short-Term Outcomes for Laparoscopic Surgery for BMI≥30 Patients with Rectal Cancer
por: Zhang, Qi, et al.
Publicado: (2021)

Abstract 30: A randomized control trial comparing myoinositol based therapy in combination with metformin versus metformin monotherapy on the clinical and hormonal parameters in obese reproductive age women with polycystic ovarian syndrome
por: Nazirudeen, Roshan, et al.
Publicado: (2022)

Metformin-associated lactic acidosis and factors associated with 30-day mortality
por: Thammavaranucupt, Kanin, et al.
Publicado: (2022)

Effects of Laparoscopic Roux-en-Y Gastric Bypass for Type 2 Diabetes Mellitus: Comparison of BMI > 30 and < 30 kg/m(2)
por: Ke, Zhigang, et al.
Publicado: (2017)

In Defense of Merit to Overcome Merit
por: Daraio, Cinzia
Publicado: (2021)

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
por: Caturano, Alfredo, et al.
Publicado: (2023)

Sleeve Gastrectomy Outcomes in Patients with BMI Between 30 and 35–3 Years of Follow-Up
por: Berry, Marcos A., et al.
Publicado: (2017)

The Asian Cardiovascular and Thoracic Annals turns 30
por: Mestres, Carlos A, et al.
Publicado: (2022)

Secondary Failure of Metformin Monotherapy in Clinical Practice
por: Brown, Jonathan B., et al.
Publicado: (2010)

Patient vs provider perspectives of 30-day hospital readmissions
por: Smeraglio, Andrea, et al.
Publicado: (2019)

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
por: Li, Tian, et al.
Publicado: (2021)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Upregulated miR-18a-5p in Colony Forming Unit-Hill’s in Subclinical Cardiovascular Disease and Metformin Therapy; MERIT Study †
por: Phowira, Jason, et al.
Publicado: (2022)

Impact of Baseline BMI on Glycemic Control and Weight Change with Metformin Monotherapy in Chinese Type 2 Diabetes Patients: Phase IV Open-Label Trial
por: Ji, Linong, et al.
Publicado: (2013)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

MERIT Guidelines
por: Stappers, Sara
Publicado: (2017)

Recognition of merit
Publicado: (2016)

Recognition of Merit
Publicado: (2012)

Recognition of merit
Publicado: (2008)

Recognition of merit
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n990krak7bejk3kijr200a2mj0